Charles Sternberg, Associate Editor12.06.23
Bone Health Technologies (BHT), an innovator in health technologies to improve bone health, has been granted its fourth patent to further its commercialization of the Osteoboost device, which has been shown in clinical trials to reduce the loss of bone mass in post-menopausal women.
The Osteoboost patent recognizes the invention as a wearable apparatus focused on the treatment or prevention of osteopenia or osteoporosis. It stimulates bone growth and preserves bone mineral density by sending low-frequency vibrations to the targeted area. The vibrating pieces are secured to the user laterally and are monitored and regulated via multiple accelerometers.
“Over 63 million Americans have low bone density, yet the field has been lacking new therapies with no new agents in clinical trials - innovations such as Osteoboost are critical to turning around the public health trajectory of fractures,” said Laura Yecies, CEO of Bone Health Technologies.
“My motivation to invent a novel solution for low bone density resulted directly from my experience treating so many patients with painful vertebral compression fractures. I was determined to develop a non-drug treatment that patients would be interested in using and could incorporate into their daily lives to prevent the loss of bone that results in fractures,” according to Dr. Shane Mangrum, Founder, of Bone Health Technologies.
Recently, Bone Health Technologies filed for Class 2 Prescription De Novo Approval with the FDA and was previously awarded Breakthrough Device Status.
Bone Health Technologies says it is honored to be a recipient of an additional patent and is optimistic about future developments of the Osteoboost as they strive to continue forwarding their work.
The Osteoboost patent recognizes the invention as a wearable apparatus focused on the treatment or prevention of osteopenia or osteoporosis. It stimulates bone growth and preserves bone mineral density by sending low-frequency vibrations to the targeted area. The vibrating pieces are secured to the user laterally and are monitored and regulated via multiple accelerometers.
“Over 63 million Americans have low bone density, yet the field has been lacking new therapies with no new agents in clinical trials - innovations such as Osteoboost are critical to turning around the public health trajectory of fractures,” said Laura Yecies, CEO of Bone Health Technologies.
“My motivation to invent a novel solution for low bone density resulted directly from my experience treating so many patients with painful vertebral compression fractures. I was determined to develop a non-drug treatment that patients would be interested in using and could incorporate into their daily lives to prevent the loss of bone that results in fractures,” according to Dr. Shane Mangrum, Founder, of Bone Health Technologies.
Recently, Bone Health Technologies filed for Class 2 Prescription De Novo Approval with the FDA and was previously awarded Breakthrough Device Status.
Bone Health Technologies says it is honored to be a recipient of an additional patent and is optimistic about future developments of the Osteoboost as they strive to continue forwarding their work.